Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer.

Stabile A, Dell'Oglio P, Soligo M, De Cobelli F, Gandaglia G, Fossati N, Esposito A, Brembilla G, Karnes RJ, Montorsi F, Briganti A.

Eur Urol Oncol. 2019 Jun 13. pii: S2588-9311(19)30073-2. doi: 10.1016/j.euo.2019.05.006. [Epub ahead of print]

PMID:
31204312
2.

Cost-Effectiveness of Active Surveillance, Radical Prostatectomy, and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.

Sharma V, Wymer KM, Borah BJ, Barocas DA, Thompson RH, Karnes RJ, Boorjian SA.

J Urol. 2019 May 21:101097JU0000000000000345. doi: 10.1097/JU.0000000000000345. [Epub ahead of print]

PMID:
31112105
3.

Defining "High Risk" for Men with Localized Prostate Cancer: How Close Can Clinical Parameters Get Us?

Mason RJ, Joniau S, Karnes RJ.

Eur Urol Oncol. 2018 Jun;1(2):149-150. doi: 10.1016/j.euo.2018.04.009. Epub 2018 May 15. No abstract available.

PMID:
31100239
4.

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.

Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, Grubmüller B, Gandaglia G, Briganti A, Karnes RJ.

Eur Urol Oncol. 2018 May;1(1):46-53. doi: 10.1016/j.euo.2018.03.002. Epub 2018 May 15.

PMID:
31100228
5.

Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches.

Gontero P, Marra G, Alessio P, Filippini C, Oderda M, Munoz F, Linares E, Sanchez-Salas R, Challacombe B, Dasgupta P, Goonewardene S, Popert R, Cahill D, Gillatt D, Persad R, Palou J, Joniau S, Piechaud T, Morlacco A, Vidit S, Roupret M, De La Taille A, Albisinni S, Gandaglia G, Mottrie A, Joshi S, Fiscus G, Berger A, Aron M, Van Der Poel H, Tilki D, Lawrentschuk N, Murphy DG, Leung G, Davis J, Karnes RJ.

J Urol. 2019 May 10:101097JU0000000000000327. doi: 10.1097/JU.0000000000000327. [Epub ahead of print]

PMID:
31075058
6.

Contemporary Trends in Magnetic Resonance Imaging at the Time of Prostate Biopsy: Results from a Large Private Insurance Database.

Kim SP, Karnes RJ, Mwangi R, Van Houten H, Gross CP, Gershman B, Leapman MS, Shah ND.

Eur Urol Focus. 2019 Apr 29. pii: S2405-4569(19)30102-6. doi: 10.1016/j.euf.2019.03.016. [Epub ahead of print]

PMID:
31047904
7.

Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases.

Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ.

Adv Radiat Oncol. 2019 Feb 19;4(2):314-322. doi: 10.1016/j.adro.2019.02.002. eCollection 2019 Apr-Jun.

8.

Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review.

Calleris G, Marra G, Dalmasso E, Falcone M, Karnes RJ, Morlacco A, Oderda M, Sanchez-Salas R, Soria F, Gontero P.

World J Urol. 2019 Apr 6. doi: 10.1007/s00345-019-02749-z. [Epub ahead of print]

PMID:
30955047
10.

Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence.

Wymer KM, Sharma V, Davis BJ, Kwon ED, Mynderse LA, Karnes RJ.

Clin Genitourin Cancer. 2019 Jun;17(3):e536-e540. doi: 10.1016/j.clgc.2019.01.019. Epub 2019 Feb 6. No abstract available.

PMID:
30902522
11.

Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years.

Karnes RJ, Motterle G.

Eur Urol. 2019 Jun;75(6):1035-1036. doi: 10.1016/j.eururo.2019.02.025. Epub 2019 Mar 1. No abstract available.

PMID:
30827693
12.

Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience.

Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Tarrel R, Quevedo FJ, Cheville JC, Karnes RJ.

World J Urol. 2019 Feb 25. doi: 10.1007/s00345-019-02689-8. [Epub ahead of print]

PMID:
30805684
13.

Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study.

Fossati N, Robesti D, Karnes RJ, Soligo M, Boorjian SA, Bossi A, Coraggio G, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Scarcella S, Bartkowiak D, Böhmer D, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A.

Eur Urol. 2019 Feb 21. pii: S0302-2838(19)30112-5. doi: 10.1016/j.eururo.2019.02.004. [Epub ahead of print]

PMID:
30799187
14.

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M.

Cancer Cell. 2019 Mar 18;35(3):401-413.e6. doi: 10.1016/j.ccell.2019.01.008. Epub 2019 Feb 14.

PMID:
30773341
15.

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00036. Epub 2018 Jul 24.

16.

EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.

Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H.

EMBO J. 2019 Mar 1;38(5). pii: e99599. doi: 10.15252/embj.201899599. Epub 2019 Feb 5.

PMID:
30723117
17.

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications.

Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ, Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED, Davis BJ, Nathan MA.

Adv Radiat Oncol. 2018 Sep 5;4(1):79-89. doi: 10.1016/j.adro.2018.08.022. eCollection 2019 Jan-Mar.

18.

Comprehensive characterization of perioperative reoperation following radical cystectomy.

Lyon TD, Boorjian SA, Shah PH, Tarrell R, Cheville JC, Frank I, Karnes RJ, Thompson RH, Tollefson MK.

Urol Oncol. 2019 Apr;37(4):292.e11-292.e17. doi: 10.1016/j.urolonc.2018.11.023. Epub 2019 Jan 22.

PMID:
30679081
19.

Impact of time from biopsy to surgery on complications, functional and oncologic outcomes following radical prostatectomy.

Westerman ME, Sharma V, Bailey GC, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Karnes RJ.

Int Braz J Urol. 2019 May-Jun;45(3):468-477. doi: 10.1590/S1677-5538.IBJU.2018.0196.

20.

Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.

Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Quevedo FJ, Cheville JC, Karnes RJ.

BJU Int. 2019 Jun;123(6):1011-1019. doi: 10.1111/bju.14612. Epub 2019 Jan 8.

PMID:
30623554
21.

Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer.

Vasmatzis G, Kosari F, Murphy SJ, Terra S, Kovtun IV, Harris FR, Zarei S, Smadbeck JB, Johnson SH, Gaitatzes AG, Therneau TM, Rangel LJ, Knudson RA, Greipp P, Sukov WR, Knutson DL, Kloft-Nelson SM, Karnes RJ, Cheville JC.

Mayo Clin Proc. 2019 Jan;94(1):27-36. doi: 10.1016/j.mayocp.2018.06.028.

PMID:
30611450
22.

Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancer.

Moschini M, Sharma V, Soligo M, Psutka S, Rangel L, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Karnes RJ.

Scand J Urol. 2018 Oct - Dec;52(5-6):340-348. doi: 10.1080/21681805.2018.1534886. Epub 2019 Jan 2.

PMID:
30600747
23.

Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.

Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):584-590. doi: 10.1158/1055-9965.EPI-18-0667. Epub 2018 Nov 12.

PMID:
30420441
24.

Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.

Gandaglia G, Soligo M, Battaglia A, Muilwijk T, Robesti D, Mazzone E, Barletta F, Fossati N, Moschini M, Bandini M, Joniau S, Karnes RJ, Montorsi F, Briganti A.

Eur Urol. 2019 May;75(5):817-825. doi: 10.1016/j.eururo.2018.10.042. Epub 2018 Nov 5.

PMID:
30409676
25.

A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease.

Lyon TD, Frank I, Sharma V, Shah PH, Tollefson MK, Thompson RH, Karnes RJ, Thapa P, Cheville JC, Boorjian SA.

World J Urol. 2018 Nov 3. doi: 10.1007/s00345-018-2551-9. [Epub ahead of print]

PMID:
30392012
26.

Radiotherapy for newly diagnosed oligometastatic prostate cancer.

Boeri L, Sharma V, Karnes RJ.

Lancet. 2018 Dec 1;392(10162):2327-2328. doi: 10.1016/S0140-6736(18)32598-4. Epub 2018 Oct 21. No abstract available.

27.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141.

PMID:
30321406
28.

Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.

Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A.

Eur Urol. 2019 Jan;75(1):176-183. doi: 10.1016/j.eururo.2018.09.009. Epub 2018 Oct 6.

PMID:
30301694
29.

Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy.

Oderda M, Joniau S, Palazzetti A, Falcone M, Melloni G, Van Den Bossche H, Deconinck S, Zattoni F, Karnes RJ, Gontero P.

Eur Urol Focus. 2018 Mar;4(2):288-293. doi: 10.1016/j.euf.2015.12.004. Epub 2015 Dec 24.

PMID:
30205893
30.

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.

Soria F, Pisano F, Gontero P, Palou J, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes JA, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Sylvester R.

World J Urol. 2018 Nov;36(11):1775-1781. doi: 10.1007/s00345-018-2450-0. Epub 2018 Aug 31.

PMID:
30171454
31.

Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort.

Karnes RJ, MacKintosh FR, Morrell CH, Rawson L, Sprenkle PC, Kattan MW, Colicchia M, Neville TB.

Front Oncol. 2018 Aug 6;8:296. doi: 10.3389/fonc.2018.00296. eCollection 2018.

32.

Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. doi: 10.1158/1055-9965.EPI-18-0369. Epub 2018 Aug 14.

PMID:
30108099
33.

Genomic diversity in low-risk disease: present and future.

Sharma V, Karnes RJ.

Nat Rev Urol. 2018 Oct;15(10):594-596. doi: 10.1038/s41585-018-0073-2. No abstract available.

PMID:
30097623
34.

Much ado about robotic versus open radical prostatectomy.

Sharma V, Karnes RJ.

Lancet Oncol. 2018 Aug;19(8):1003-1004. doi: 10.1016/S1470-2045(18)30417-0. Epub 2018 Jul 17. No abstract available.

PMID:
30017350
35.

Temporal trends in venous thromboembolism after radical cystectomy.

Lyon TD, Tollefson MK, Shah PH, Bews K, Frank I, Karnes RJ, Thompson RH, Habermann EB, Boorjian SA.

Urol Oncol. 2018 Aug;36(8):361.e15-361.e21. doi: 10.1016/j.urolonc.2018.05.015. Epub 2018 Jun 7.

PMID:
29885792
36.

Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer.

Bhindi B, Karnes RJ.

Eur Urol. 2018 Oct;74(4):534-535. doi: 10.1016/j.eururo.2018.05.021. Epub 2018 Jun 14. No abstract available.

PMID:
29866462
37.

The Association of Aspirin Use with Survival Following Radical Cystectomy.

Lyon TD, Frank I, Shah PH, Tarrell R, Cheville JC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA.

J Urol. 2018 Nov;200(5):1014-1021. doi: 10.1016/j.juro.2018.05.119. Epub 2018 May 30.

PMID:
29857079
38.

Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.

Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM.

Clin Cancer Res. 2018 Aug 15;24(16):3908-3916. doi: 10.1158/1078-0432.CCR-17-2745. Epub 2018 May 14.

39.

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC.

Gigascience. 2018 Jun 1;7(6). doi: 10.1093/gigascience/giy050.

40.

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.

Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Gontero P.

World J Urol. 2018 Oct;36(10):1621-1627. doi: 10.1007/s00345-018-2299-2. Epub 2018 May 2.

PMID:
29721611
41.

Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.

Ravi P, Karnes RJ, Rangel LJ, Pagliaro LC.

J Urol. 2018 Nov;200(5):1075-1081. doi: 10.1016/j.juro.2018.04.070. Epub 2018 Apr 27.

PMID:
29709664
42.

Examining the association between adiposity and biochemical recurrence after radical prostatectomy.

Mason RJ, Boorjian SA, Bhindi B, Rangel L, Frank I, Karnes RJ, Tollefson MK.

Can Urol Assoc J. 2018 Jul;12(7):E331-E337. doi: 10.5489/cuaj.4923. Epub 2018 Mar 19.

43.

More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis.

Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Bartkowiak D, Wiegel T, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A, Boorjian SA.

Eur Urol. 2018 Aug;74(2):134-137. doi: 10.1016/j.eururo.2018.02.024. Epub 2018 Mar 12.

PMID:
29544737
44.

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.

Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P.

Eur Urol Focus. 2018 Mar 10. pii: S2405-4569(18)30077-4. doi: 10.1016/j.euf.2018.02.015. [Epub ahead of print]

PMID:
29530632
45.

Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.

Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H.

EMBO Mol Med. 2018 Apr;10(4). pii: e8478. doi: 10.15252/emmm.201708478.

46.

Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.

Abou-Ouf H, Alshalalfa M, Takhar M, Erho N, Donnelly B, Davicioni E, Karnes RJ, Bismar TA.

J Cancer Res Clin Oncol. 2018 May;144(5):883-891. doi: 10.1007/s00432-018-2615-7. Epub 2018 Mar 6.

PMID:
29511883
47.

Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.

Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM.

Mol Cancer Res. 2018 Apr;16(4):643-654. doi: 10.1158/1541-7786.MCR-17-0539. Epub 2018 Feb 16.

48.

Is it time for a more 'proactive' approach to metastatic prostate cancer?

Soligo M, Sharma V, Karnes RJ.

BJU Int. 2018 Feb;121(2):167-168. doi: 10.1111/bju.14107. No abstract available.

49.

Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?

Nguyen DP, Vertosick EA, Sharma V, Corradi RB, Vilaseca A, Takeda T, Sjoberg DD, Benfante N, Fine SW, Reuter VE, Scardino PT, Eastham JA, Karnes RJ, Touijer KA.

J Urol. 2018 Jun;199(6):1502-1509. doi: 10.1016/j.juro.2017.12.056. Epub 2018 Jan 4.

PMID:
29307681
50.

Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.

Colicchia M, Morlacco A, Rangel LJ, Carlson RE, Dal Moro F, Karnes RJ.

Eur Urol Focus. 2018 Jan 3. pii: S2405-4569(17)30292-4. doi: 10.1016/j.euf.2017.12.005. [Epub ahead of print]

PMID:
29306730

Supplemental Content

Loading ...
Support Center